These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 13212905)

  • 41. Biological basis for chemohormonal therapy for prostatic cancer.
    Isaacs JT; Kyprianou N
    Cancer Treat Res; 1989; 46():177-93. PubMed ID: 2577189
    [No Abstract]   [Full Text] [Related]  

  • 42. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Halland A; Jønler M; Pedersen KV
    Scand J Urol Nephrol; 2005; 39(1):87-8. PubMed ID: 15764279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone replacement therapy and the risk of prostate cancer.
    Warburton D; Hobaugh C; Wang G; Lin H; Wang R
    Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Re: Testosterone therapy in men with untreated prostate cancer. A. Morgentaler, L. I. Lipshultz, R. Bennett, M. Sweeney, D. Avila, Jr. and M. Khera. J Urol 2011; 185: 1256-1261.
    Friedman AE
    J Urol; 2011 Oct; 186(4):1559; author reply 1560. PubMed ID: 21907684
    [No Abstract]   [Full Text] [Related]  

  • 45. Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists.
    Clyne M
    Nat Rev Urol; 2013 Dec; 10(12):679. PubMed ID: 24247426
    [No Abstract]   [Full Text] [Related]  

  • 46. [Determination of male hormones in prostatic adenoma and cancer of the prostate].
    TORTIGUE
    J Urol Medicale Chir; 1950; 56(1-2):98-101. PubMed ID: 15422673
    [No Abstract]   [Full Text] [Related]  

  • 47. A rational approach to androgen therapy for hypogonadal men with prostate cancer.
    Kaufman J
    Int J Impot Res; 2006; 18(1):26-31. PubMed ID: 16208401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Andropause, male climacteric and crisis of the fifties: should androgens be administered?].
    Martin-Du Pan R; Martin-du Pan S; Sindelar P
    Rev Med Suisse Romande; 1995 Mar; 115(3):257-62. PubMed ID: 7777768
    [No Abstract]   [Full Text] [Related]  

  • 49. Androgen replacement therapy after prostate cancer treatment.
    Khera M
    Curr Urol Rep; 2010 Nov; 11(6):393-9. PubMed ID: 20838944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Theoretical presuppositions and clinical findings on the use of bi-sexual steroids in prostatic adenoma; preliminary note].
    CORRADO F
    Minerva Urol; 1958; 10(2):38-40. PubMed ID: 13552454
    [No Abstract]   [Full Text] [Related]  

  • 51. Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.
    Bokhorst LP; Heesterman BL
    Eur Urol; 2022 Oct; 82(4):441. PubMed ID: 35902289
    [No Abstract]   [Full Text] [Related]  

  • 52. [Treatment of prostatic cancer].
    Lehtonen T; Mäntylä M
    Duodecim; 1979; 95(12):760-7. PubMed ID: 520197
    [No Abstract]   [Full Text] [Related]  

  • 53. Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.
    Akaza H
    Curr Urol Rep; 2016 Nov; 17(11):84. PubMed ID: 27696248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advancements in radiotherapy and improved outcomes in prostate cancer.
    Milito SJ; Thomas CR; Turrisi AT
    J S C Med Assoc; 1998 Jun; 94(6):257-62. PubMed ID: 9648407
    [No Abstract]   [Full Text] [Related]  

  • 55. Managing prostate cancer.
    Gillmore R
    Practitioner; 2004 Apr; 248(1657):274-80. PubMed ID: 15114817
    [No Abstract]   [Full Text] [Related]  

  • 56. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
    Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Long-term treatment of medullary insufficiency with androgens].
    Najean Y; Dresh C; Laprevotte I
    Minerva Med; 1971 Jun; 62(51):2588-97. PubMed ID: 5566872
    [No Abstract]   [Full Text] [Related]  

  • 58. [Isolated testicular mass revealing a metastasis of prostate adenocarcinoma].
    Hommell J; Ragage F; Pinatel B; Ruffion A; Decaussin-Petrucci M
    Ann Pathol; 2009 Dec; 29(6):488-90. PubMed ID: 20005437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgens and prostate cancer; pathogenesis and deprivation therapy.
    Grossmann M; Cheung AS; Zajac JD
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):603-16. PubMed ID: 24054933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention.
    Montironi R; Mazzucchelli R; Scarpelli M
    Ann N Y Acad Sci; 2002 Jun; 963():169-84. PubMed ID: 12095942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.